Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRL1 | P41146 | 18/20 | 0.65 |
| ▸ | OPRM1 | P35372 | 13/20 | 0.65 |
| ▸ | OPRK1 | P41145 | 3/20 | 0.62 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23699058 | 1.00 | OPRL1 (0.65) | OPRL1OPRM1OPRK1 | |
| SCHEMBL23699051 | 1.00 | OPRL1 (0.65) | OPRL1OPRM1OPRK1 | |
| SCHEMBL5164120 | 0.81 | OPRL1 (0.60) | OPRL1OPRM1OPRK1 | |
| Ethylbenzene SCHEMBL11065452 | 0.81 | OPRM1 (0.55) | OPRL1OPRM1OPRK1 | |
| SCHEMBL4348575 | 0.80 | OPRL1 (0.59) | OPRL1OPRM1 | |
| Hydrochloric Acid SCHEMBL5165769 | 0.80 | OPRL1 (0.61) | OPRL1OPRM1OPRK1 | |
| SCHEMBL4357610 | 0.79 | OPRL1 (0.70) | OPRL1OPRM1OPRK1 | |
| SCHEMBL5164651 | 0.79 | OPRL1 (0.72) | OPRL1OPRM1OPRK1 | |
| SCHEMBL5167830 | 0.79 | OPRL1 (0.57) | OPRL1OPRM1OPRK1 | |
| SCHEMBL5165953 | 0.79 | OPRL1 (1.00) | OPRL1OPRM1OPRK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3858810-A1 | DIALKYLAMINOARYLCYCLOALKYLAMIDE DERIVATIVES HAVING MULTIMODAL ACTIVITY AGAINST PAIN | ESTEVE PHARMACEUTICALS, S.A. (ES) | 2021-08-04 | — | — | EP | disclosed |
| EP-3858810-A1 | DIALKYLAMINOARYLCYCLOALKYLAMIDE DERIVATIVES HAVING MULTIMODAL ACTIVITY AGAINST PAIN | ESTEVE PHARMACEUTICALS, S.A. (ES) | 2021-08-04 | — | — | EP | disclosed |
| US-9580386-B2 | Substituted 4-aminocyclohexane derivatives | GRÜNENTHAL (DE) | 2017-02-28 | — | — | US | disclosed |
| US-9403767-B2 | Substituted 4-aminocyclohexane derivatives | GRUENENTHAL GMBH (DE) | 2016-08-02 | — | — | US | disclosed |
| US-20140357634-A1 | SUBSTITUTED 4-AMINOCYCLOHEXANE DERIVATIVES | Grünenthal GmbH (DE) | 2014-12-04 | — | — | US | disclosed |
| US-8835689-B2 | Substituted 4-aminocyclohexane derivatives | Grünenthal GmbH (DE) | 2014-09-16 | — | — | US | disclosed |
| US-20130197095-A1 | SUBSTITUTED 4-AMINOCYCLOHEXANE DERIVATIVES | Grünenthal GmbH (DE) | 2013-08-01 | — | — | US | disclosed |
| US-20120202810-A1 | SUBSTITUTED 4-AMINOCYCLOHEXANE DERIVATIVES | GRUNENTHAL GMBH (DE) | 2012-08-09 | — | — | US | disclosed |
| US-20090247530-A1 | SUBSTITUTED 4-AMINOCYCLOHEXANE DERIVATIVES | GRUNENTHAL GMBH (DE) | 2009-10-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140357634-A1 | SUBSTITUTED 4-AMINOCYCLOHEXANE DERIVATIVES | OPRL1, OPRK1, OPRD1 | OPRL1 1/4885OPRM1 4/4885OPRK1 2/4885 |
| US-20090247530-A1 | SUBSTITUTED 4-AMINOCYCLOHEXANE DERIVATIVES | OPRL1, OPRK1, OPRD1 | OPRL1 1/4885OPRM1 4/4885OPRK1 2/4885 |
| US-20120202810-A1 | SUBSTITUTED 4-AMINOCYCLOHEXANE DERIVATIVES | OPRL1, OPRK1, OPRD1 | OPRL1 1/4885OPRM1 4/4885OPRK1 2/4885 |
| US-20130197095-A1 | SUBSTITUTED 4-AMINOCYCLOHEXANE DERIVATIVES | OPRL1, OPRK1, OPRD1 | OPRL1 1/4885OPRM1 4/4885OPRK1 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.